Grace Therapeutics, Inc. — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1e3138cf-2fde-40da-854c-3d2afb7e14db/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-11.1M | 2025-04-01 – 2026-03-31 | evidence 0001140361-26-025662 |
| FY 2024 | $-16.7M | 2024-04-01 – 2025-03-31 | evidence 0001140361-25-023259 |
| FY 2023 | $-12.9M | 2023-04-01 – 2024-03-31 | evidence 0000950170-24-075875 |
| FY 2022 | $-52.2M | 2022-04-01 – 2023-03-31 | evidence 0000950170-23-029498 |
| FY 2021 | $-15.6M | 2021-04-01 – 2022-03-31 | evidence 0000950170-22-011842 |
| FY 2020 | $-16.4M | 2020-04-01 – 2021-03-31 | evidence 0001171843-21-004462 |
| FY 2019 | $-24.4M | 2019-04-01 – 2020-03-31 | evidence 0001171843-20-004613 |
| FY 2018 | $-34.4M | 2018-04-01 – 2019-03-31 | evidence 0001171843-20-004613 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).